Assessing the use of sodium-glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and chronic kidney disease in tertiary care: a SwissDiab Study
Authors' conclusion
A divergence between recommended standard of care and implementation in daily clinical practice was observed. Although treatment should always consider patient-specific circumstances, the results highlight the need to reinforce current treatment recommendations to ensure patients benefit from the best available care.
Study context
- Population
- Outpatients in tertiary diabetes care in the Swiss Diabetes Registry with T2D and a study visit January 1, 2020–March 31, 2021364 analysed
- Participants
- 368 outpatients
- Outcome
- Prevalence of CKD (eGFR <60 mL/min/1.73 m² and/or persistent albuminuria per KDIGO) and proportion of patients with CKD prescribed SGLT2i
Methodological detailsregistry-based (Swiss Diabetes Registry), retrospective medical record review, Excluded due to missing data: 1.1% (n=4)
- Registry-based (Swiss Diabetes Registry)
- Retrospective medical record review
- Excluded due to missing data: 1.1% (n=4)
Main finding
As reported in the abstract
Chronic kidney disease (CKD) prevalence
47.3%
n=172
SGLT2i prescribed among patients with CKD
32.6%
n=56
Observational data: associations, not effects.
Further findings
SGLT2i treatment already in 2018 among those prescribed
- On SGLT2i already in 2018, before renoprotective effects established
- 75%
Documented reasons for non-treatment with SGLT2i (116 patients with CKD without SGLT2i)
- Known contraindications
- 19.0%
- Stopped treatment due to adverse events
- 9.5%
- Other reasons
- 5.2%
- No underlying reason identified
- 66.4%
Original publication
Assessing the use of sodium-glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and chronic kidney disease in tertiary care: a SwissDiab Study. BMJ Open Diabetes Res Care. Published 19 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →